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Abstract Approximately 60% of VACTERL (vertebral
defects, anal atresia, cardiac defects, tracheoesophageal
fistula with atresia, renal defects/radial limb dysplasia)
patients have renal anomalies that can be associated with
chronic kidney disease (CKD). With improved medical
care, a large proportion of these patients survive into
adulthood. Longitudinal follow-up data regarding the
management of kidney disease in these children is lacking.
Twelve VACTERL patients with CKD stage 2–5 and 12
age-matched controls with similar urologic anomalies and
CKD [mean follow-up period 15.0±1.4 (SE) and 11.9±2.1
years, respectively] were identified in a single center. Eight
VACTERL patients progressed to end-stage renal disease
(ESRD) compared to four controls (66.7 vs. 33.3%,
respectively). Six VACTERL patients were dialyzed pre-
transplant. Of the four patients on peritoneal dialysis (PD),
three had to be switched to hemodialysis due to complica-
tions, whereas two of the three controls on PD did not
experience significant problems. Seven VACTERL patients
underwent renal transplantation compared to four controls.
Mean creatinine clearance 2 years post-transplant was 65.8±
6.3 in VACTERL patients vs. 87.8±7.1 ml/min per 1.73 m2
in controls (p=0.03). VACTERL patients had a significant-
ly lower mean height standard deviation score than the
controls (−2.34±0.41 vs. −1.27±0.24, respectively; p<
0.05). Based on these results, VACTERL patients with
CKD develop ESRD more frequently, experience more
complications with dialysis, may have a poorer transplant
outcome, and have more severe growth failure than
controls.
Keywords Chronic kidney disease . Dialysis . Short stature .
Transplant . VACTERL association
Introduction
The VATER association refers to a group of congenital
malformations that includes vertebral defects, anal atresia,
cardiac defects, tracheoesophageal fistula with atresia, renal
defects, and radial upper limb dysplasia. The association
was first described by Quan and Smith [1], and since then
the description has been extended to include cardiac (C)
and limb defects (L), with the resulting acronym of
VACTERL [2, 3]. Temtamy et al. suggested that the V in
VATER could also include vascular defects, such as
ventricular septal defect (VSD) and single umbilical artery
(SUA) [4].
Although some cases of VACTERL association have
been found to be related to chromosomal trisomy and
deletion defects [5], the VACTERL association is generally
not related to a chromosomal abnormality. The anomalies
appear to arise from developmental abnormalities of the
mesoderm of the involved organs during early embryogen-
esis (<35 days), when the origins of the lumbosacral spine,
genitourinary tract, and hindgut are located closely together
[6]. There have been increasing reports of VACTERL
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association in infants of mothers with diabetes mellitus [7, 8].
The malformations in the offspring of diabetic mothers occur
before the seventh gestational week, similar to the period
when the developmental abnormalities responsible for
VACTERL association arise, suggesting a possible causal
relationship [9].
Renal anomalies are found in approximately 60–90% of
VACTERL patients. Uehling et al. reported genitourinary
involvement in 21 of 23 children with VATER association,
including renal agenesis (seven cases), severe reflux (nine
cases), crossed fused ectopia (five cases), and ureteropelvic
junction obstruction (five cases) [10]. Thirteen patients in
their study required more than one surgical urologic
intervention. Three patients were on hemodialysis (HD)
for renal failure, and one patient had a renal transplantation.
Weber et al. reported renal malformations in 20 of 30 patients
(67%) with VATER association, with the most common
anomalies being renal agenesis (nine cases), unilateral
hypoplasia and contralateral uretero-pelvic obstruction
(four cases), crossed renal ectopia (three cases), and horseshoe
kidney (two cases) [11].
Although renal anomalies occur at a high frequency in
VACTERL association and the management of these
problems is a clinical challenge, especially in the setting
of multiple other medical issues, there are almost no
published reports on the clinical course of kidney disease
in VACTERL association.
Materials and methods
The records of VACTERL patients with chronic kidney
disease (CKD) stage 2–5 and age-matched controls with
similar urologic anomalies and CKD but no VACTERL
association seen at the University of California San Diego
Medical Center and Rady Children’s Hospital, San Diego
from January 1980 to December 2005 were retrospectively
reviewed. The study was approved by the Institutional
Review Board at the University of California San Diego
and Rady Children’s Hospital, San Diego.
The diagnosis of VACTERL association was made when
more than three major organ systems were involved.
Exclusion criteria in this study included patients with other
known disorders. All the patients underwent extensive
evaluations, including ultrasounds, echocardiograms, void-
ing cystourethrograms, and cystoscopy.
Creatinine clearance (CrCl, in ml/min per 1.73 m2) was
estimated using the Schwartz formula [12]. The CKD
staging was performed according to Kidney Disease Out-
comes Quality Initiative (K/DOQI) guidelines [13]. Height
standard deviation scores (SDS) were calculated by
appropriate gender- or age-specific mean and standard
deviation for the U.S. population using the National Health
and Nutrition Examination Survey (NHANES) data of the
National Center for Health Statistics and Centers for
Disease Control and Prevention [14]. Since the third
percentile for age and gender corresponds to a height SDS
of −1.88, the patients were categorized by height SDS <
−1.88 and >−1.88.
Statistical analyses were performed using SPSS for
Windows ver. 12.0 (SPSS, Chicago, IL). Comparison of
patient characteristics between VACTERL association
patients and control patients was done by the chi-square
Fisher test and Student’s t test. A p value <0.05 was
considered to be statistically significant.
Results
Twelve VACTERL patients with CKD stage 2–5 were
identified. The mean follow-up period was 15.0±1.4 (SE)
years (range 3.2–21 years), and all patients were diagnosed
at birth. Six patients (50%) were delivered prematurely.
Five (42%) were diagnosed prenatally with urological
abnormalities. Among these patients, two were diagnosed
with oligohydramnios, while one patient was diagnosed
with polyhydramnios.
Extrarenal anomalies in VACTERL patients
Extrarenal anomalies observed in the VACTERL patients
are shown in Table 1. The most common anomaly was
imperforate anus, which occurred at an incidence of 92%,
followed by cardiac anomalies (67%). The incidence of
vertebral and limb anomalies was 50 and 25%, respectively.
Limb anomalies included polydactyly, syndactyly, and
reduction deficiency. Eleven patients had surgery on more
than two organ systems, including abdominal surgery for
imperforate anus.
Table 1 Extrarenal anomalies in VACTERL patients
Extrarenal anomalies Number of cases (%)
Vertebral anomalies 6 (50)
Tracheo-esophageal fistula 3 (25)
Imperforate anus 11 (92)
Cardiac anomalies 8 (67)
Ventricular septal defect 1 (13)
Atrial septal defect 2 (25)
Patent ductus arteriosus 2 (25)
Dextrocardia 1 (13)
Septal hypertrophy 1 (13)
Limb anomalies 3 (25)
VACTERL, Vertebral defects, anal atresia, cardiac defects, tracheoe-
sophageal fistula with atresia, renal defects/radial limb dysplasia
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Renal and other urologic anomalies and intervention
Structural bladder anomalies were observed in 75% of the
VACTERL patients (Table 2). These anomalies included
duplicated, enlarged, dysplastic bladders and bladders with
diverticula. Five patients had neurogenic bladders and six
patients had cloacas. Most of the patients (92%) required
vesicostomies or intermittent catheterizations. Nine patients
underwent vesicostomies and five had subsequent take-
down with conversion to clean intermittent catheterization
(CIC). Four patients had bladder augmentation and per-
formed CIC. Eleven patients had two or more urologic
surgeries. Other renal or urologic anomalies included
dysplasia and reflux (five patients, 42%) and dysplasia,
reflux and obstruction (three patients, 25%). Urethral
abnormalities were also present, including stenotic urethra
(two patients), urethrocutaneous fistula and chordee (one
patient), and duplicated urethra (one patient).
Table 2 Renal and urologic features of VACTERL patients






to CKD stage > 2
(years)
Patient 1 F Neurogenic bladder Reflux Vesicostomy 3 3.6
Ureteral reimplant
Bladder augmentation
Patient 2 M Enlarged bladder Dysplasia Vesicostomy 3 15.8
Reflux Chordee release
Urethrocutaneous fistula Fistula repair
Chordee Nephrectomy
Rectourethral fistula




Patient 4 F Cloaca Dysplasia Vesicostomy 4 At birth
Stenotic urethra Urinary diversion
Urethroplasty
Cloacal repair





Patient 6 F Dysplasia 0 At birth
Reflux
Patient 7 F Neurogenic bladder Dysplasia Vesicostomy 3 At birth
Cloaca Reflux Urinary diversion
Patient 8 F Duplicated bladder Dysplasia Urinary diversion 2 At birth
Cloaca Reflux Cloacal repair
Patient 9 F Deformed bladder Dysplasia Vesicostomy 2 At birth
Cloaca Reflux Cloacal repair
Patient 10 M Neurogenic bladder Dysplasia Vesicostomy 6 10.3
Reflux Urinary diversion
Bulbar urethral stricture Bladder augmentation
Chordee Release of chordee
Urethral stricture repair
Patient 11 F Neurogenic bladder Vesicostomy 2 At birth
Cloaca Cloacal repair
Patient 12 F Bladder diverticulum Dysplasia Pyeloplasty 5 12.4
Neurogenic bladder Obstruction Nephrectomy
Colovesical fistula Reflux Vesicostomy
Bladder augmentation
Closure of fistula
F, Female; M, male; CKD, chronic kidney disease
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Dialysis modalities
Six VACTERL patients required dialysis. Two (33.3%)
were started on HD due to severe adhesions from more than
five previous abdominal surgeries. Four patients, who had
two or fewer previous abdominal surgeries, were initially
started on peritoneal dialysis (PD), but three were switched
to HD due to complications. One patient developed a
diaphragmatic leak 3 months after starting PD and was
switched to HD. The second patient underwent another
abdominal surgery 4 months after starting PD and was
switched to HD; she was unable to go back to PD due to
adhesions after the surgery. The third patient also had
another abdominal surgery after starting PD and several
episodes of peritonitis that may have aggravated pre-
existing adhesions; she was eventually switched to HD in
1 year. Peritoneal dialysis was not attempted again since
these patients were transplanted within 9 months after
starting HD. The one PD patient who was successfully
dialyzed had previously undergone only one abdominal
surgery (gastrostomy).
Renal Transplant
Seven VACTERL patients were transplanted. Five patients
(71.4%) received a living-related donor transplant; two
were pre-emptive transplants. Two other patients received a
deceased donor transplant. One patient on HD was unable
to receive a transplant until the end of the study period. The
time from diagnosis of end-stage renal disease (ESRD) to
renal transplant was 9.1±3.2 months. The mean CrCl
immediately post-transplant, 2 years post-transplant, and
5 years post-transplant was 88.4±8.4, 65.8±6.3, and 47.8±
6.4 ml/min per 1.73 m2, respectively (Table 3). Two
patients had graft failure.
Growth in VACTERL patients
Eight (67%) VACTERL patients had a height SDS < −1.88.
For all of these patients (male:female,1:7), growth hormone
(GH) achieved a significant improvement in height SDS:
from −3.4±0.4 to −2.6±0.5 within 2 years (p<0.05). The
mean age of the VACTERL patients at initiation of the GH
treatment was 11.3±0.9 years. One patient was at CKD
stage 4, six patients at stage 3, and one patient at stage 2 at
the initiation of GH treatment.
Comparison between VACTERL and control patients
VACTERL patients and age-matched controls with similar
urologic anomalies but no VACTERL association were
compared (Table 4). The mean follow-up period was similar
between the two groups (15.0±1.4 vs. 11.9±2.1 years,
p=0.23). Nine control patients had bladder involvement
and four had neurogenic bladder, similar to the VACTERL
patients. More patients in the VACTERL group than in the
control group reached ESRD during the study period, but
this difference was not statistically significant. Five of six
VACTERL patients were ultimately placed on HD, while
only one of the three CKD control patients was treated with
HD. VACTERL patients experienced several complications
during PD, including diaphragmatic leak and severe
abdominal adhesions that required them to switch to HD;
in comparison, none of the control patients experienced
complications that required them to switch dialysis modal-
ities. Seven VACTERL patients versus four controls were
transplanted, and the mean CrCl 2 years post-transplant was
65.8±6.3 vs. 87.8±7.1 ml/min per 1.73 m2 (p=0.03),
respectively. VACTERL patients were significantly shorter
than control patients, with the height SDS for all VACTERL
patients and control patients being −2.34±0.41 vs.
Table 3 Mean serum creatinine levels (mg/dl) and creatinine clearance (ml/min per 1.73 m2) post-transplant
Patient Age at transplant
(years)







Patient 2 18.4 1.8 (53.5) 1.8 (53.5) N/A Enlarged bladder
Patient 3 2.9 0.4 (114.8) 0.5 (97.4) 0.9 (68.1) Bladder diverticulum
Patient 4 3.8 0.6 (81.6) 0.9 (66) 1.4 (47.1) Cloaca
Patient 5a 11.1 0.8 (89.4) 1.2 (66.9) 1.5(54.8) Cloaca
Patient 7b 7.7 0.6 (94.3) 1.4 (44.5) 2.1 (33.8) Cloaca
Patient 8 1.6 0.4 (113.4) 0.7 (71.7) N/A Cloaca
Patient 11 8.1 0.8 (71.5) 1.0 (60.8) 1.9 (35.3) Cloaca
Mean CrCl (±SE) (ml/min per 1.73 m2) 88.4±8.4 65.8±6.3 47.8±6.4
CrCl, Creatinine clearance; N/A, not available due to patient being less than 5 years post-transplant
a Patient developed graft failure 7 years 9 months after transplant
b Patient developed graft failure 8 years after transplant
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−1.27±0.24 (p=0.03) prior to GH use. Eight VACTERL
patients were on GH, while one control patient was treated
with GH.
Discussion
Renal anomalies are found at a high frequency in
VACTERL association; there are, however, very few
reports on the renal course in this subset of the population
and especially in pediatric patients. We followed our
subjects over an extended period of time (15.0±1.4 years)
and have described their renal/urologic anomalies, various
aspects of their CKD, dialysis modality, and renal trans-
plant course.
Twelve patients developed CKD stage 2–5 during the
study period. Interestingly, we noted that although in
VACTERL association there is a similar ratio of males to
females (52 vs. 48%) [15], the patients who had CKD in
our study were predominantly female (75%).
Multi-organ involvement in VACTERL patients greatly
complicates medical care. Weber et al. studied 30 infants
with VATER association and reported that 21 of the patients
(70%) required major surgeries on two organ systems,
while one patient required major surgeries on three organ
systems [11]. Our patients also had multiple congenital
anomalies, and 11 underwent surgery on more than two organ
systems. These extra-renal anomalies can complicate the renal
course in VACTERL patients. For example, due to intra-
abdominal adhesions from previous surgeries, most of the
VACTERL patients in our study were on HD rather than PD.
Most VACTERL patients (92%) in our study had bladder
involvement that required urologic interventions, such as
vesicostomies, intermittent catheterizations, bladder aug-
mentation or urinary diversion. The bladder anomalies were
also accompanied by other complex urological abnormal-
ities (Table 2), similar to those reported in other studies [10,
11]. These included urethral abnormalities, such as stenotic
urethra, urethrocutaneous fistula, and chordee, and dupli-
cated urethra. Fernbach [16] reported that eight of 20
VATER patients in their study had urethral anomalies, which
included megalourethra, urethral duplication, anterior ure-
thral valve, hypospadias, and congenital stricture. Due to the
high incidence of urethral anomalies, the author recommen-
ded doing a voiding cystourethrogram on all males with
VATER association even when clinical symptoms are not
present. Since 75% of the VACTERL patients with CKD in
our study were female and most had significant bladder
anomalies, a complete urologic evaluation should be
considered for all VACTERL patients with CKD.
Eight VACTERL patients progressed to ESRD at a mean
age of 8.5±2.5 years. Six patients were started on dialysis.
Peritoneal dialysis was initially chosen as the dialysis
modality for most of the VACTERL patients due to the
many advantages it has for pediatric patients, including
greater freedom to ambulate and less interruption of daily
activities. Two patients were treated with HD only due to
multiple abdominal surgeries; three PD patients were
switched to HD due to complications, such as intra-
abdominal adhesions and diaphragmatic leak. It appears
that HD is the preferred modality for VACTERL patients
due to the high incidence of intra-abdominal surgeries and
the potential for adhesions preventing successful PD. In
accordance with our study, Uehling et al. also reported that
the ESRD patients in their study also all underwent HD,
although no mention is made on whether these patients
required HD due to complications that prevented them from
undergoing PD [10].
Seven VACTERL patients in our study were transplanted.
Patients who have congenital urologic anomalies have been
shown to be at increased risk for urinary tract infection,
surgical complications, graft dysfunction, and graft loss [17–
19]. There are conflicting reports on the management of the
lower urinary tract before and after transplantation. Alfrey et
al. reported that bladder augmentation before transplant
caused increasing hydronephrosis and infection and sug-
Table 4 Comparison between VACTERL and chronic kidney disease
control patients with urologic anomalies
Characteristics of
study cohort





Mean age at diagnosis





8/12 (67%) 4/12 (33%) 0.22
Mean age of reaching
ESRD (years)
8.5±2.5 9.3±2.7 0.82














7 /12 (58%) 4 /12 (33%)
Living-related donor
transplants
5 (71.4%) 3 (75%) 1.0
Mean CrCl (ml/min per 1.73 m2)
6 months 72.3±10.8 100.7±8.4 0.1
2 years 65.8±6.3 87.8±7.1 0.03
Values are given as mean ± standard error unless indicated otherwise
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gested takedown of bladder augmentation before transplant
[20]. Other studies, however, have shown that urinary tract
reconstruction before transplantation is safe [21–23]. Koo et
al. studied 18 patients with severe dysfunctional lower
urinary tract anomalies that included posterior urethral
valves, urogenital sinus anomalies, prune-belly syndrome,
complete bladder duplication, and ureterocele [22]. Eleven
patients underwent bladder augmentation or continent
urinary diversion, while two had an intestinal conduit and
five had a transplant into the native bladder. These
researchers reported a patient survival of 100% and an
allograft survival of 81% during a 4.4-year follow-up period,
which were similar to the values of all the children who
underwent renal transplantation in their center. They there-
fore concluded that renal transplantation in patients with
lower urinary tract dysfunction was successful and that
bladder reconstruction could be safely performed before and
after transplant. In our study, all seven patients who
underwent renal transplant had severe lower urinary tract
anomalies, and six patients underwent urinary reconstruction
prior to transplant. Among the five patients with CrCl <
70 ml/min per 1.73 m2 at 2 years post-transplant (Table 3),
four had a cloaca and one had an enlarged bladder; the other
two patients with CrCl > 70 ml/min per 1.73 m2 had a cloaca
and a bladder diverticulum. Although patient 3 with only
bladder diverticulum had the best post-transplant function at
2 years (97.4 ml/min per 1.73 m2) and 5 years (68.1 ml/min
per 1.73 m2), our study group is much too small to draw any
conclusions about whether severe VACTERL bladder
anomalies may have contributed to poor transplant graft
function and outcome. Patients 5 and 7, both with cloaca,
had graft failure by 8 years (71% graft survival by 8 years).
VACTERL patients have been noted to have growth
deficiency. In a study of 31 VATER patients, 45% of the
patients showed postnatal growth deficiency of at least −2
SDS for the first 3 years of life or beyond [24]. Severe
cardiac defect was correlated to the growth deficiency in
nine patients, but no cause for the growth deficiency in the
other patients was noted. Khadilkar et al. found that
VATER patients did not demonstrate GH deficiency and
did not appear to have pituitary dysfunction [25]. Only one
of their VATER patients had vertebral anomalies, and so
this would not have explained the short stature. Unlike the
VACTERL patients in our study, however, patients in the
study by Khadilkar et al. did not have CKD.
In our study, eight (67%) VACTERL patients had a
height SDS <−1.88. This was a significantly higher
percentage compared to the North American Pediatric
Renal Trials and Collaborative Studies (NAPRTCS) data-
base, where CKD patients with a height SDS ≤−1.88
comprised 36.9% of the patient cohort [26]. Late treatment
with GH may have been a factor in the short stature of the
VACTERL patients since they were treated with GH late in
childhood (mean age at GH initiation 11.3±0.9 years).
Since 9/12 patients had CKD stage > 2 when less than
4 years old (Table 2), earlier treatment with GH may have
resulted in an improved height SDS. Faster progression of
CKD and late treatment with GH could be the reason for
the poorer growth in VACTERL patients compared to that
in the control patients prior to GH use.
Other factors that could have contributed to the short
stature in VACTERL patients include feeding difficul-
ties, especially for patients with T-E fistula, multiple
surgeries, CKD stage, and cardiovascular anomalies.
However, we could not find a significant correlation
between these factors and short stature for our patients.
One limitation of our study is the small number of
patients. With a larger study number, a more apparent
cause may be uncovered.
In order to observe the effect that the VACTERL
association had on the course of renal disease, we
identified age-matched controls with similar urologic
anomalies to the VACTERL patients but without
VACTERL association. There was no significant differ-
ence in the number of patients with bladder anomalies
between the control and VACTERL patients, and the
bladder anomalies were similar in nature. Therefore,
bladder anomalies did not appear to be responsible for
the higher frequency of ESRD and poor outcome after
renal transplantation in VACTERL patients. Further-
more, Khositseth et al. reported no difference in graft
function between kidney transplant recipients with
obstructive and reflux uropathy and the controls over a
10-year period [27]. This may indicate that factors other
than urologic anomalies may influence graft function in
VACTERL patients, especially since these patients had
multiple other medical issues.
The small number of subjects limited our ability to
determine the prognostic factors for short stature and
development of graft dysfunction. More data would be
required to obtain statistically significant conclusions.
With improving medical care, more VACTERL patients
are surviving into adulthood. There are, however, very few
reports on the renal course and complications of VAC-
TERL association patients. This population has an array of
complex anomalies that make treating CKD difficult.
Describing the clinical course, treatment, and outcome of
kidney disease in VACTERL association patients may
help clinicians treat this population. Further study of the
various complications that can arise during treatment of
VACTERL patients, the modes of intervention that may be
required, and the timing of these interventions may lead to
improved treatment and outcomes.
Acknowledgments We gratefully acknowledge the invaluable assis-
tance provided by Dina MacDonald, RN.
1052 Pediatr Nephrol (2009) 24:1047–1053
Conflicts of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Quan L, Smith DW (1973) The VATER association. Vertebral
defects, Anal atresia, T-E fistula with esophageal atresia, radial
and renal dysplasia: a spectrum of associated defects. J Pediatr 82
(1):104–107
2. Kaufman RL (1973) Birth defects and oral contraceptives. Lancet
1(7816):1396
3. Nora AH, Nora JJ (1975) A syndrome of multiple congenital
anomalies associated with teratogenic exposure. Arch Environ
Health 30(1):17–21
4. Temtamy SA, Miller JD (1974) Extending the scope of the
VATER association: definition of the VATER syndrome. J Pediatr
85(3):345–349
5. McNeal RM, Skoglund RR, Francke U (1977) Congenital
anomalies including the VATER association in a patient with del
(6)q deletion. J Pediatr 91(6):957–960
6. Gilbert E, Optiz J (1979) Renal involvement in genetic-hereditary
malformation syndromes. In: Hamburger J, Crosnier J, Grunfeld JP
(eds) Nephrology. John Wiley, New York, pp 909–944
7. Boutte P, Valla JS, Lambert JC, Tordjman C, Berard E, Mariani R
(1985) The Vater association in a newborn infant of a diabetic
mother. Pediatrie 40(3):219–222
8. Castori M, Rinaldi R, Capocaccia P, Roggini M, Grammatico P
(2008) VACTERL association and maternal diabetes: a possible
causal relationship? Birth Defects Res A Clin Mol Teratol 82
(3):169–172
9. Mills JL, Baker L, Goldman AS (1979) Malformations in infants
of diabetic mothers occur before the seventh gestational week.
Implications for treatment. Diabetes 28(4):292–293
10. Uehling DT, Gilbert E, Chesney R (1983) Urologic implications
of the VATER association. J Urol 129(2):352–354
11. Weber TR, Smith W, Grosfeld JL (1980) Surgical experience in
infants with the VATER association. J Pediatr Surg 15(6):849–854
12. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976)
A simple estimate of glomerular filtration rate in children
derived from body length and plasma creatinine. Pediatrics 58
(2):259–263
13. Eknoyan G, Levin N (2002) K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification.
Am J Kidney Dis 39[2 Suppl 1]:S14–S214
14. Centers for Disease Control and Prevention (2000). National
Center for Health Statistics. National Health and Nutrition
Examination Survey Data. Available at: http://www.cdc.gov/
nchs/about/major/nhanes
15. Weaver DD, Mapstone CL, Yu PL (1986) The VATER association.
Analysis of 46 patients. Am J Dis Child 140(3):225–229
16. Fernbach SK (1991) Urethral abnormalities in male neonates with
VATER association. AJR Am J Roentgenol 156(1):137–140
17. Churchill BM, Sheldon CA, McLorie GA, Arbus GS (1988)
Factors influencing patient and graft survival in 300 cadaveric
pediatric renal transplants. J Urol 140(5 Pt 2):1129–1133
18. Mochon M, Kaiser BA, Dunn S, Palmer J, Polinsky MS,
Schulman SL, Flynn JT, Baluarte HJ (1992) Urinary tract
infections in children with posterior urethral valves after kidney
transplantation. J Urol 148(6):1874–1876
19. Adams J, Mehls O, Wiesel M (2004) Pediatric renal transplanta-
tion and the dysfunctional bladder. Transpl Int 17(10):596–602
20. Alfrey EJ, Salvatierra O Jr, Tanney DC, Mak R, Scandling JD,
Dafoe DC, Hammer GB, Orlandi PD, Page L, Conley SB (1997)
Bladder augmentation can be problematic with renal failure and
transplantation. Pediatr Nephrol 11(6):672–675
21. DeFoor W, Minevich E, McEnery P, Tackett L, Reeves D,
Sheldon C (2003) Lower urinary tract reconstruction is safe and
effective in children with end stage renal disease. J Urol 170(4 Pt
2):1497–1500
22. Koo HP, Bunchman TE, Flynn JT, Punch JD, Schwartz AC,
Bloom DA (1999) Renal transplantation in children with severe
lower urinary tract dysfunction. J Urol 161(1):240–245
23. Sheldon CA, Gonzalez R, Burns MW, Gilbert A, Buson H,
Mitchell ME (1994) Renal transplantation into the dysfunctional
bladder: the role of adjunctive bladder reconstruction. J Urol
152(3):972–975
24. Mapstone CL, Weaver DD, Yu PL (1986) Analysis of growth in
the VATER association. Am J Dis Child 140(4):386–390
25. Khadilkar VV, Cameron FJ, Stanhope R (1999) Growth failure
and pituitary function in CHARGE and VATER associations.
Arch Dis Child 80(2):167–170
26. Seikaly MG, Salhab N, Gipson D, Yiu V, Stablein D (2006)
Stature in children with chronic kidney disease: analysis of
NAPRTCS database. Pediatr Nephrol 21(6):793–799
27. Khositseth S, Askiti V, Nevins TE, Matas AJ, Ingulli EG,
Najarian JS, Gillingham KJ, Chavers BM (2007) Increased
urologic complications in children after kidney transplants for
obstructive and reflux uropathy. Am J Transplant 7(9):2152–2157
Pediatr Nephrol (2009) 24:1047–1053 1053
